- ￥6666
- CUSABIO
- CN
- CSB-EP001105HU
- 2025年07月15日
企业认证
相关产品推荐更多 >
TXNDC17/TXNDC17蛋白/14KDA thioredoxin-related protein ;TRP14Protein 42-9-9Thioredoxin-like protein 5蛋白/Recombinant Human Thioredoxin domain-containing protein 17 (TXNDC17)重组蛋白
￥69
Recombinant-Haloferax-volcanii-Protein-translocase-subunit-SecDsecDProtein translocase subunit SecD
￥13440
Recombinant-Protein-sbmAsbmAProtein sbmA
￥12390
Recombinant-Haemophilus-influenzae-Arginine-ABC-transporter-permease-protein-ArtMartMArginine ABC transporter permease protein ArtM
￥10794
CYP11B2/CYP11B2蛋白Recombinant Human Cytochrome P450 11B2, mitochondrial (CYP11B2)重组蛋白Aldosterone synthase蛋白
￥2208
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
见说明书
- 保质期：
见说明书
- 英文名：
Recombinant Human Tyrosine-protein kinase ABL1(ABL1) ,partial
- 库存：
99
- 供应商：
武汉华美生物/CUSABIO
- 规格：
20ug/100ug/1mg
ABL1蛋白|Recombinant Human Tyrosine-protein kinase ABL1(ABL1) ,partial|大肠杆菌/毕赤酵母/哺乳动物细胞/杆状病毒-昆虫细胞/无细胞 五大表达系统
Uniprot ID：P00519
别名：Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; ABL; ABL proto oncogene 1 non receptor tyrosine kinase; ABL1; ABL1_人; bcr/abl; bcr/c abl oncogene protein; c ABL; c abl oncogene 1 non receptor tyrosine kinase; c abl oncogene 1 receptor tyrosine kinase; c ABL1; JTK7; p150; Proto oncogene tyrosine protein kinase ABL1; Proto-oncogene c-Abl; Tyrosine-protein kinase ABL1; v abl Abelson murine leukemia viral oncogene homolog 1; v abl
种属：Homo sapiens (Human)
氨基酸序列：参见官网
微信ID: Cusabio01 电话： 027-87939808
详情请登录：www.cusabio.cn
| 华美生物︱YOUR GOOD PARTNER IN BIOLOGY RESEARCH! | |
| 武汉华美生物工程有限公司成立于2007年12月，是一家集科研、生产、销售为一体的生物高新技术企业。并形成了以CUSABIO为品牌的ELISA试剂盒、外泌体提取试剂盒、蛋白、抗体等多种优质产品，远销欧美日德等九十多个国家。 推荐您微信关注华美官方公众号，方便查询产品，同时获取生命科学更新资讯！ |
|
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Quantitative BCR-ABL1 RQ-PCR Fusion Transcript Monitoring in Chronic Myelogenous Leukemia
The reciprocal Philadelphia translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)] creates a BCR-ABL1 fusion protein that occurs in approximately 95% of cases of chronic myelogenous leukemia (CML), 15% of cases of adult acute
The reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11), Philadelphia chromosome] creates a BCR-ABL1 fusion protein that occurs in approximately 95% of cases of chronic myelogenous leukemia (CML), 15% of cases of adult
Chronic Myeloid Leukemia: Cytogenetic Methods and Applications for Diagnosis and Treatment
to an accelerated disease phase or a terminal blast crisis. Because new frontline therapies such as imatinib specifically target the abnormal protein product of the BCR–ABL1 fusion gene to eliminate BCR–ABL1 positive cells, there is a new reliance on the cytogenetic
技术资料暂无技术资料 索取技术资料
